The neutralization phenotypes of HIV-1 mAbs and polyclonal mixtures from subjects VC10014 and VC20013 were determined using neutralization assays against heterologous pseudoviruses from the indicated clades. The values reported here shaded in grey are the IC50 values of neutralization as antibody concentration in μg/mL. The percent breadth reported is calculated by dividing the number of pseudoviruses for which an IC50 was recorded by the total number of pseudoviruses tested and multiplying by 100.</p
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In th...
<p>The two R880F mAbs, 19.3H-L1 (<b>A</b>) and 19.3H-L3 (<b>B</b>), in conjunction with 16-month (<b...
<p>The graphs show percent neutralization versus BMS purified IgG (A) or IgA (B) dilution. The corre...
<p>Summary of neutralization breadth of individual mAbs from previously published experiments. The c...
<p>Shown is the breadth of neutralization for each serum sample against a panel of 10 pseudoviruses ...
<p>The neutralization curves of anti-V3 mAb 2191 against nine selected HIV-1 pseudoviruses are shown...
<p>A. Analysis on the relationship between the reduction of neutralizing activities after V3 peptide...
<p>Sera from 50 HIV-1 subtype A-infected patients were tested in the TZM-bl neutralization assay aga...
<p>The neutralization breadth of plasma antibodies from 6 plasma samples obtained from HIV-1 infecte...
<p>Neutralizing activity of immune serum to 18 clade A, B, and C HIV-1 isolates was measured in the ...
Induction of antibodies that neutralize a broad range of human immunodeficiency virus type 1 (HIV-1)...
Several new human monoclonal antibodies (mAbs) with a neutralizing potential across different subtyp...
<p>% Neutralization obtained with 1∶20 plasma dilution, ≥80% reduction in virus titer is highlighted...
The development of a rapid and efficient system to identify human immunodeficiency virus type 1 (HIV...
<p>The neutralization breadth of plasma antibodies from 2 samples of HIV-1 infected ART-naive indivi...
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In th...
<p>The two R880F mAbs, 19.3H-L1 (<b>A</b>) and 19.3H-L3 (<b>B</b>), in conjunction with 16-month (<b...
<p>The graphs show percent neutralization versus BMS purified IgG (A) or IgA (B) dilution. The corre...
<p>Summary of neutralization breadth of individual mAbs from previously published experiments. The c...
<p>Shown is the breadth of neutralization for each serum sample against a panel of 10 pseudoviruses ...
<p>The neutralization curves of anti-V3 mAb 2191 against nine selected HIV-1 pseudoviruses are shown...
<p>A. Analysis on the relationship between the reduction of neutralizing activities after V3 peptide...
<p>Sera from 50 HIV-1 subtype A-infected patients were tested in the TZM-bl neutralization assay aga...
<p>The neutralization breadth of plasma antibodies from 6 plasma samples obtained from HIV-1 infecte...
<p>Neutralizing activity of immune serum to 18 clade A, B, and C HIV-1 isolates was measured in the ...
Induction of antibodies that neutralize a broad range of human immunodeficiency virus type 1 (HIV-1)...
Several new human monoclonal antibodies (mAbs) with a neutralizing potential across different subtyp...
<p>% Neutralization obtained with 1∶20 plasma dilution, ≥80% reduction in virus titer is highlighted...
The development of a rapid and efficient system to identify human immunodeficiency virus type 1 (HIV...
<p>The neutralization breadth of plasma antibodies from 2 samples of HIV-1 infected ART-naive indivi...
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In th...
<p>The two R880F mAbs, 19.3H-L1 (<b>A</b>) and 19.3H-L3 (<b>B</b>), in conjunction with 16-month (<b...
<p>The graphs show percent neutralization versus BMS purified IgG (A) or IgA (B) dilution. The corre...